DNDi no MedTrop2025: ciência e diálogo com a sociedade

Comissão Europeia investe 20 milhões de euros para desenvolver medicamentos urgentes contra a dengue em parceria com a AFD e a DNDi

Host-derived molecules as novel chagas disease biomarkers: hypercoagulability markers and extracellular vesicles

Comissão Europeia anuncia investimento de 20 ME em medicamentos contra dengue

10 de novembro de 2025 – 15 de novembro de 2025, GMT-3

Belém, Pará

DNDi na COP30

eNews América Latina – Outubro, 2025

Target product profile and discovery and development path for novel cryptococcal disease treatments

Rede Fiocruz de Pesquisa Clínica debate cooperação científica e desafios sanitários

Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)

New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial

Performance evaluation of rapid diagnostic tests for Chagas disease in Jutiapa, Guatemala

2 de novembro de 2025 – 5 de novembro de 2025, GMT-3

João Pessoa, Paraíba

MedTrop 2025

Abordagem de ciência aberta resulta em candidato promissor em fase pré-clínica para antiviral de amplo espectro contra coronavírus

Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans

Structure–activity relationships of fenarimol analogues with potent in vitro and in vivo activity against Madurella mycetomatis, the main causative agent of eumycetoma

DNDi cria comitê consultivo comunitário para América Latina